Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma

Ann Hematol. 2009 Sep;88(9):921-2. doi: 10.1007/s00277-008-0692-4. Epub 2009 Jan 13.

Authors

Adrian Tempescul¹, Jean-Christophe Ianotto, Frederic Morel, Veronique Marion, Marc De Braekeleer, Christian Berthou

Affiliation

¹ Department of Clinical Hematology, Institute of Cancerology and Hematology, CHU Morvan, Brest, France. [email protected]

PMID: 19139889
DOI: 10.1007/s00277-008-0692-4

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Female
Humans
Lenalidomide
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / genetics
Recurrence
Remission Induction
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use

Substances

Antineoplastic Agents
Thalidomide
Lenalidomide